Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value
$1.98−0.18 (-8.33%)
Close on Nov 12, 2026Market cap $24.73MP/E –Yield –
Aligos Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Aligos Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -1137.2%. For fiscal 2025 it was -1106.7%, against -3633.6% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1106.7% | +2526.9 |
| FY2024 | Dec 31, 2024 | -3633.6% | −2217.4 |
| FY2023 | Dec 31, 2023 | -1416.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -772.4% | +871.4 |
| Q1 FY2026 | Mar 31, 2026 | -814.1% | −14668.8 |
| Q4 FY2025 | Dec 31, 2025 | -11763.9% | +1792.2 |
| Q3 FY2025 | Sep 30, 2025 | -4256.0% | −2715.3 |
| Q2 FY2025 | Jun 30, 2025 | -1643.8% | −2120.8 |
| Q1 FY2025 | Mar 31, 2025 | 13854.7% | +18878.1 |
| Q4 FY2024 | Dec 31, 2024 | -13556.1% | −9405.5 |
| Q3 FY2024 | Sep 30, 2024 | -1540.7% | +122.0 |
| Q2 FY2024 | Jun 30, 2024 | 477.0% | +914.6 |
| Q1 FY2024 | Mar 31, 2024 | -5023.5% | +11372.9 |
| Q4 FY2023 | Dec 31, 2023 | -4150.6% | – |
| Q3 FY2023 | Sep 30, 2023 | -1662.8% | – |
| Q2 FY2023 | Jun 30, 2023 | -437.6% | – |
| Q1 FY2023 | Mar 31, 2023 | -16396.4% | – |
See a number that looks wrong?